GlassScriptPhysician profile
Barbara G Smith
NPI 1124151170
$1,310.28
in general payments reported to CMS, 2019-2025
22 companies · $201 in 2025
The $201 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $305 · 2022: $50.70 · 2023: $461 · 2024: $293 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $955.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $954.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $281.49 | 2023-2024 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $224.78 | 2023-2025 | |
| Alcon Vision LLC | $120.16 | 2021 | |
| Astellas Pharma US INC | $99.00 | 2021 | |
| Dexcom, INC. | $67.81 | 2023 | Dexcom G6 Transmitter |
| Amgen INC. | $56.64 | 2024-2025 | Otezla, Repatha, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53.63 | 2025 | Caplyta |
| Lilly USA, LLC | $52.80 | 2023-2025 | Mounjaro, Zepbound |
| Collegium Pharmaceutical, INC. | $46.14 | 2024 | Belbuca |
| Astrazeneca Pharmaceuticals LP | $42.55 | 2021-2024 | Breztri |
| Pfizer INC. | $40.63 | 2021-2023 | |
| Axsome Therapeutics, INC. | $36.08 | 2025 | Auvelity |
| Hikma Pharmaceuticals USA | $35.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.61 | 2023 | Jardiance |
| Intra-Sana Laboratories | $20.26 | 2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $19.98 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $18.34 | 2021 | |
| Arbor Pharmaceuticals, INC. | $15.70 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $14.62 | 2021 | |
| Glaxosmithkline, LLC. | $14.37 | 2025 | Trelegy Ellipta |
| Biodelivery Sciences International, INC. | $13.00 | 2021 | |
| Redhill Biopharma INC. | $12.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.